The biopharmaceutical company Aruvant Sciences, Inc has appointed V. “Palani” Palaniappan as chief technology officer with a brief to optimise the manufacturing process for gene therapies for sickle cell disease. Dr Palaniappan has 25 years experience in research and drug development and has joins Aruvant from Sarepta Therapeutics Inc where he was head of global technical operations. Dr Palaniappan has bachelor's and master's degrees from Annamalai University in India, and a doctorate in chemistry from the Indian Institute of Technology in Kanpur.
Aruvant Sciences Inc announced this appointment on 1 June 2020
Copyright 2020 Evernow Publishing Ltd